Axamon (Ipidakrin) 20 mg, 50 pcs.

1 tablet contains:

active substance:

ipidacrine hydrochloride monohydrate (Axamon) 20 mg (in terms of ipidacrine hydrochloride);

excipients :

ludipress (lactose monohydrate 93%, povidone 3.5%, crospovidone 3.5%) 65 mg,

sodium carboxymethyl starch 14 mg,

calcium stearate 1 mg.

Pharmacodynamics .

Reversible cholinesterase inhibitor. Due to blockade of potassium channels of cell membranes and inhibition of cholinesterase activity, it stimulates neuromuscular transmission and conduction of impulses in the nervous system.

It has an M- and H-cholinomimetic effect. Enhances the effect of acetylcholine, serotonin, histamine and oxytocin on smooth muscles, resulting in increased contractility of smooth muscle organs, including The gastrointestinal tract and bronchi, reduces heart rate, enhances the secretion of salivary glands, contractile activity of the myometrium, and tonus of skeletal muscles.

It has a stimulating effect on the central nervous system in combination with certain manifestations of a sedative effect; contributes to improved learning and memory.

Pharmacokinetics .

Quickly absorbed from the gastrointestinal tract. The maximum concentration in plasma is reached after one hour. 

40-55% of the active substance binds to plasma proteins.

The half-life is about 40 minutes. Metabolized in the liver.

Excretion is carried out through the kidneys (mainly by tubular secretion and only 1/3 of the drug is excreted by glomerular filtration), as well as extrarenal (through the gastrointestinal tract).

• Diseases of the peripheral nervous system (neuritis, polyneuritis and polyneuropathy, polyradiculopathy, myasthenia gravis and myasthenic syndrome of various etiologies);
• The recovery period of organic lesions of the central nervous system, accompanied by motor disorders, including bulbar paralysis and paresis;
• Combined therapy of demyelinating diseases;
• Senile dementia, Alzheimer's disease, encephalopathy of various origins.

The use of the drug increases the tone of the uterus and can lead to premature birth, therefore ipidacrine is contraindicated during pregnancy.

Data on the use of the drug during breastfeeding are not available.

Hypersensitivity to any of the components of the drug, epilepsy, extrapyramidal disorders with hyperkinesis, angina pectoris, severe bradycardia, bronchial asthma, mechanical obstruction of the intestines or urinary tract, vestibular disorders, gastric ulcer or duodenal ulcer in the stage of exacerbation of lactose intolerance, intolerance, galactose malabsorption, pregnancy and lactation, children under 18 years of age.

With caution in: gastric and duodenal ulcer in remission, thyrotoxicosis, cardiac conduction disturbances; a history of obstructive diseases of the respiratory system or with acute diseases of the respiratory tract.

Caused by the excitation of m-cholinergic receptors: salivation, increased sweating, nausea, diarrhea, jaundice, bradycardia, epigastric pain, increased secretion of bronchial secretions, bronchospasm, convulsions, increased uterine tone.

Drooling and bradycardia can be reduced 

m-anticholinergics: atropine, trihexyphenidyl (cyclodol), metocinium iodide (metacin), etc.

Less commonly, after applying higher doses, dizziness, ataxia, headache, vomiting, general weakness, drowsiness, and skin reactions (itching, rash) were observed. In these cases, the dose is reduced or the drug is interrupted for a short time (1-2 days).

Axamon® enhances sedation in combination with drugs that inhibit the central nervous system.

The effect and side effects are enhanced when combined with other cholinesterase inhibitors and m-cholinomimetic agents.

In patients with myasthenia gravis, the risk of developing a cholinergic crisis increases if Axamon® is used simultaneously with other cholinergic agents.

The risk of developing bradycardia increases if β-blockers were used before treatment with Axamon®.

It attenuates the inhibitory effect on neuromuscular transmission and the excitation of peripheral nerves of local anesthetics, aminoglycosides, potassium chloride.

Axamon® can be used in combination with nootropic drugs.

Alcohol enhances the side effects of the drug.

Inside. Doses and duration of treatment are determined individually depending on the severity of the disease.

Diseases of the peripheral nervous system, myasthenia gravis, myasthenic syndrome: 10-20 mg 1-3 times a day. The course of treatment is from one to two months. If necessary, the course of treatment can be repeated several times with a break between courses of 1-2 months.

Alzheimer's disease, encephalopathy, the recovery period of organic diseases of the central nervous system, accompanied by motor disorders, including bulbar paralysis and paresis: the daily dose is selected individually, usually 10-20 mg 2-3 times a day.

With demyelinating lesions of the nervous system, the dose can be increased to 20-40 mg 5-6 times a day. The maximum daily dose of 200 mg.

If one of the doses was missed, then the next dose is taken in the usual dose. 

Symptoms : loss of appetite, bronchospasm, lacrimation, increased sweating, narrowing of the pupils, nystagmus, increased motility of the gastrointestinal tract, spontaneous defecation and urination, vomiting, jaundice, bradycardia, disturbance of intracardiac conduction, arrhythmia, anxiety, decreased blood pressure , feeling of fear, ataxia, convulsions, coma, speech impairment, drowsiness, and general weakness.

Treatment: the use of m-anticholinergics (atropine, cyclodol, metacin, etc.), symptomatic therapy.

During treatment, one should refrain from driving a car, other vehicles and mechanisms, as well as from engaging in potentially dangerous activities that require an increased concentration of attention and speed of psychomotor reactions.

Pills.